Rheumatoid Arthritis News

The slow march toward precision medicine in rheumatoid arthritis features increased use of serum biomarkers and novel approaches to biopsy, but “a ton of hurdles” remain, according to a presenter at the Biologic Therapies Summit.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.

DESTIN, Fla. — Efficacy is just one of many factors that should be considered when choosing therapies for rheumatoid arthritis and psoriatic arthritis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Making sense of the myriad targets for the myriad disease domains in rheumatoid arthritis and psoriatic arthritis presents ongoing challenges for every rheumatologist, a presenter said here..

Patients with pre-existing rheumatoid arthritis can safely undergo immune checkpoint inhibition for the treatment of cancer, albeit with close monitoring for flares, according to data published in The Lancet Rheumatology.

Mehret Birru Talabi, MD, PhD, associate program director of the rheumatology fellowship training program at the University of Pittsburgh Medical Center, spoke with Healio about challenges patients with rheumatology face with fertility, how their RA symptoms are affected during pregnancy, and what they can to help improve their symptoms after giving birth.

Patients with rheumatoid arthritis who receive an etanercept biosimilar demonstrate similar disease activity and survival outcomes as those who receive the originator product, according to data published in Rheumatology.

Patients aged 65 years and older or who have ever smoked are at higher risk for malignancies, major adverse cardiovascular events, myocardial infarction and all-cause death when using tofacitinib vs. TNF inhibitors, according to data.

Systemic immune-inflammation index scores may act as an important indicator of a patients’ risk for developing rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.